3Murphy S, Peterson P,Iland H, et al. Experience of the Polycythemia Vera StudyGroup with essential thrombocythemia：a final report on diagnostic criteria,survival,andleukemic transition by treatment .Semin Hematol,1997,34：29～39
4Basses C, Cervantes F, Pereira A, et al. Major vascular complications in essentialthrombocythemia：a study of the predictive factors in a series of 148 patients.Leukemia,1999,13：150～154
5Sterkers Y, Preudhomme C,Lai JL, et al. Acute myeloid leukemia and myelodysplasticsyndromes following essential thrombocythaemia treated with hydroxyura：high proportionof cases with 17p deletion. Blood,1998,91：616～622
6Barbui T, Finazzi G, Dupuy E, et al. Treatment strategies in essentialthrombocythemia：a critical appraisal of various experiences in different centers.Leukemia and Lymphoma,1996,22(Suppl 1)：149～160
收稿 1999-03-30
修回 1999-09-10
7Murphy S,Peterson P,Iland H,et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria,survival, and leukemic transition by treatment [ J ]. Semin Hematol, 1997,34 ( 1 ) :29-39.
8Perezeneinas M M, Bellolope J L,Pere C C. C-reaction protein in differential diagnosis of primary thrombocytosis [J]. Med Clin, 1996,104 ( 12 ) :441 ~-43.
9Howland W S,Carlon G C. Critical care of the cancer patient [M]. Chicago : Year Book Medical Publishers, 1985.219 -221.
